Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Processa Pharmaceuticals third quarter 2022 earnings call and corporate update. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this call is being recorded. It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. Thank you, sir. You may begin. Thank you and welcome to Procesa's third quarter 2022 results and clinical update conference call. We are very pleased to have recently reported positive results from our ongoing phase 1b trial for PCS6422 in GI cancer and from our recently completed phase 2a trial for PCS12852 in gastroparesis. Dr. Young will discuss these later during the call. Joining me on the call today are our Chief Executive Officer, Dr. David Young, and our Chief Operating Officer, Mike Floyd. Shortly before this call, we filed our September 30, 2022 Form 10-Q, and this morning issued a press release containing preliminary results from our PCS-12-852 gastroparesis trial. I want to remind everyone that a PowerPoint presentation will accompany Dr. Young's prepared remarks. To view the PowerPoint slides, please go to the Investor Relations section on our website or our earnings press release and click on the webcast link to follow along. I will start our call by reading the Safe Harbor Statement. This statement is made pursuant to the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking within the meaning of Section 27 of the Securities Act of 1933 and Section 21 of the Securities Act of 1934. Although we believe expectations and assumptions reflected in the forw...